Report
Specialty Pharmacy Data Value Management
Contracted specialty pharmacies and hubs provide patient status and dispensing data to the manufacturer. Integration of patient statuses and dispense datasets provide a 360 patient ...
White Paper
Do Pharma Companies Need To Rethink Their Sales Operations Design?
The COVID-19 pandemic has brought about many long-term changes to the pharma industry. One area that has seen effects directly caused by COVID-19 has been in sales operations desig ...
White Paper
Coronavirus Pandemic Effects On Incentive Compensation
This paper focuses on coronavirus pandemic effects on IC for pharma companies in the short-term, medium-term, and long-term, while also providing prescriptive actions for sales exe ...
White Paper
Designing A Patient-Centric Commercial Strategy
This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...
White Paper
Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?
Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...
White Paper
Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary
This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...
White Paper
AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy
This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...
White Paper
How Will The Next Great Recession Affect The US Pharma Industry?
The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...
White Paper
Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?
Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...
White Paper
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...
White Paper
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...
Report
How Regulatory Changes Are Driving The Future Of The Medical Device Industry
With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...
White Paper
Perspectives On Pharma Company Use Of Open Payments Data
This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...
White Paper
How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?
The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...
White Paper
Is The CVS-Aetna Merger A Pharma Industry Transformative Event?
US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...
White Paper
The Causes and Solutions of Chronic Drug Shortages in the United States
While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...
White Paper
The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics
Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...
White Paper
The Reasons for and Solutions to Chronic Drug Shortages in the United States
This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...
White Paper
Pricing and Market Effects of Biosimilar Entry in the US
This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...
White Paper
Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies
President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...
Blog
Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics
The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...
White Paper
Make US Pharma Great Again!? – Part 2
Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...
White Paper
Make US Pharma Great Again!? – Part 1
The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...
White Paper
Econometric Analysis Of Biopharmaceutical Transfer Pricing
The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...
White Paper
Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?
The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...
White Paper
Patient Claims Versus EHR Data – How To Choose Between The Two?
The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...
White Paper
Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?
The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...
White Paper
The Relationship Between Drug Price Controls And Patient Health Outcomes
No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...
White Paper
The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment
The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...
White Paper
Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics
The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...
White Paper
Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems
There has been an immense improvement of theory and algorithms in recent times leading to enhancement in computation power. Also, online data availability was never easier than now ...
